Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Susan Slaugenhaupt
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
PTC Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Slaugenhaupt is a paid consultant for PTC Therapeutics. The company is developing small-molecule drugs that target post-transcriptional control processes. This research grant is studying splicing modulator compounds (SMCs). New IP resulting from this grant may be of interest to the company. The Committee on Outside Activities review panel evaluated Dr. Slaugenhaupt’s financial interest in connection with the research project and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Optimization of compounds to improve mRNA splicing in familial dysautonomia
Familial dysautonomia is a severe neurodevelopmental disease that is caused by a mutation in the IKBKAP gene. This mutations leads to reduced protein expression in all tissues, but this reduction is variable and is most severe in neuronal tissue. We have identified a compound, kinetin, that can increase IKAP protein in patient cells, and the goal of this proposal is to chemically optimize the potency and activity of kinetin in orde to develop an effective treatment for FD.
Filed on February 17, 2017.
Tell us what you know about Susan Slaugenhaupt's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Susan Slaugenhaupt filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Susan Slaugenhaupt | Massachusetts General Hospital | Conflict of Interest | PTC Therapeutics | $20,000 - $39,999 |
| Susan Slaugenhaupt | Massachusetts General Hospital | Conflict of Interest | PTC Therapeutics | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.